Rafarma Pharmaceuticals Inc
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wou… Read more
Rafarma Pharmaceuticals Inc (RAFA) - Net Assets
Latest net assets as of March 2025: $10.38 Million USD
Based on the latest financial reports, Rafarma Pharmaceuticals Inc (RAFA) has net assets worth $10.38 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.03 Million) and total liabilities ($1.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.38 Million |
| % of Total Assets | 86.31% |
| Annual Growth Rate | 11.88% |
| 5-Year Change | -86.67% |
| 10-Year Change | 13.71% |
| Growth Volatility | 3342.15 |
Rafarma Pharmaceuticals Inc - Net Assets Trend (2010–2024)
This chart illustrates how Rafarma Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Rafarma Pharmaceuticals Inc (2010–2024)
The table below shows the annual net assets of Rafarma Pharmaceuticals Inc from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $10.38 Million | -1.22% |
| 2023-12-31 | $10.51 Million | +0.33% |
| 2023-11-30 | $10.47 Million | -86.55% |
| 2022-12-31 | $77.89 Million | 0.00% |
| 2022-11-30 | $77.89 Million | +12.07% |
| 2021-12-31 | $69.50 Million | 0.00% |
| 2021-11-30 | $69.50 Million | +33.42% |
| 2020-12-31 | $52.09 Million | 0.00% |
| 2020-11-30 | $52.09 Million | +470.66% |
| 2019-12-31 | $9.13 Million | 0.00% |
| 2019-11-30 | $9.13 Million | +51.53% |
| 2018-12-31 | $6.02 Million | 0.00% |
| 2018-11-30 | $6.02 Million | +0.38% |
| 2017-12-31 | $6.00 Million | 0.00% |
| 2017-11-30 | $6.00 Million | -98.70% |
| 2014-12-31 | $460.05 Million | 0.00% |
| 2014-11-30 | $460.05 Million | +0.02% |
| 2013-12-31 | $459.96 Million | 0.00% |
| 2013-11-30 | $459.96 Million | +39.49% |
| 2011-11-30 | $329.75 Million | +15348.97% |
| 2010-11-30 | $2.13 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rafarma Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 427.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $280.00K | 2.70% |
| Common Stock | $87.00K | 0.84% |
| Other Comprehensive Income | $10.00 Million | 96.34% |
| Other Components | $13.00K | 0.13% |
| Total Equity | $10.38 Million | 100.00% |
Rafarma Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Rafarma Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SBM HOLDINGS LTD
SEM:SBMH
|
$1.35K |
|
Intercontinental Gold and Metals Ltd
PINK:GXMLF
|
$1.35K |
|
Shearwater Group plc
LSE:SWG
|
$1.35K |
|
Crescent Cotton Mills Limited
KAR:CCM
|
$1.35K |
|
Altus Property Ventures Inc
PSE:APVI
|
$1.35K |
|
Wasco Greenergy Berhad
KLSE:5343
|
$1.34K |
|
RUBICN RES
BE:D9V
|
$1.34K |
|
O0K0
F:O0K0
|
$1.34K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rafarma Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,509,000 to 10,381,000, a change of -128,000 (-1.2%).
- Net income of 266,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 1,000.
- Other factors decreased equity by 393,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $266.00K | +2.56% |
| Other Comprehensive Income | $-1.00K | -0.01% |
| Other Changes | $-393.00K | -3.79% |
| Total Change | $- | -1.22% |
Book Value vs Market Value Analysis
This analysis compares Rafarma Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-11-30 | $0.00 | $0.14 | x |
| 2011-11-30 | $0.00 | $0.14 | x |
| 2013-11-30 | $5.92 | $0.14 | x |
| 2013-12-31 | $5.92 | $0.14 | x |
| 2014-11-30 | $5.55 | $0.14 | x |
| 2014-12-31 | $5.55 | $0.14 | x |
| 2017-11-30 | $0.07 | $0.14 | x |
| 2017-12-31 | $0.07 | $0.14 | x |
| 2018-11-30 | $0.07 | $0.14 | x |
| 2018-12-31 | $0.07 | $0.14 | x |
| 2019-11-30 | $0.10 | $0.14 | x |
| 2019-12-31 | $0.10 | $0.14 | x |
| 2020-11-30 | $0.59 | $0.14 | x |
| 2020-12-31 | $0.59 | $0.14 | x |
| 2021-11-30 | $0.79 | $0.14 | x |
| 2021-12-31 | $0.79 | $0.14 | x |
| 2022-11-30 | $0.89 | $0.14 | x |
| 2022-12-31 | $0.89 | $0.14 | x |
| 2023-11-30 | $0.12 | $0.14 | x |
| 2023-12-31 | $0.12 | $0.14 | x |
| 2024-12-31 | $0.12 | $0.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rafarma Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.93%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.16x
- Recent ROE (2.56%) is below the historical average (8.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -5.49% | -87.92% | 0.06x | 1.11x | $-330.67K |
| 2011 | -0.04% | -87.92% | 0.00x | 1.00x | $-33.06 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 1.00x | $-46.02 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 1.00x | $-46.02 Million |
| 2017 | -1.62% | -77.59% | 0.02x | 1.05x | $-697.24K |
| 2017 | -1.62% | -77.59% | 0.02x | 1.05x | $-697.24K |
| 2018 | -0.10% | -4.20% | 0.02x | 1.05x | $-608.65K |
| 2018 | -0.10% | -4.20% | 0.02x | 1.05x | $-608.65K |
| 2019 | 33.45% | 26.69% | 0.56x | 2.25x | $2.14 Million |
| 2019 | 33.45% | 26.69% | 0.56x | 2.25x | $2.14 Million |
| 2020 | 28.50% | 19.87% | 1.06x | 1.36x | $9.64 Million |
| 2020 | 28.50% | 19.87% | 1.06x | 1.36x | $9.64 Million |
| 2021 | 16.65% | 14.95% | 0.87x | 1.29x | $4.62 Million |
| 2021 | 16.65% | 14.95% | 0.87x | 1.29x | $4.62 Million |
| 2022 | 6.37% | 7.71% | 0.65x | 1.26x | $-2.83 Million |
| 2022 | 6.37% | 7.71% | 0.65x | 1.26x | $-2.83 Million |
| 2023 | 2.61% | 2.69% | 0.84x | 1.16x | $-774.30K |
| 2023 | 2.60% | 2.69% | 0.83x | 1.16x | $-777.90K |
| 2024 | 2.56% | 2.93% | 0.75x | 1.16x | $-772.10K |
Industry Comparison
This section compares Rafarma Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rafarma Pharmaceuticals Inc (RAFA) | $10.38 Million | -5.49% | 0.16x | $1.35K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |